Patients received 45 mg/d of oral upadacitinib for 12 weeks across 29 French centres; all had prior exposure to at least one biologic or drug. Clinical activity was evaluated using the Harvey ...

Upadacitinib and deucravacitinib consistently were in the top two across efficacy measures. Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment ...

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).

If approved, upadacitinib would be the first and only oral advanced ... The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were ...

AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq; 15 mg, once ...

AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion recommending the approval of upadacitinib for the treatment of ...

If approved, upadacitinib would be the first and only ... reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia ...